Wells Fargo analyst Derek Archila raised the firm’s price target on Kyverna Therapeutics (KYTX) to $31 from $27 and keeps an Overweight rating on the shares. The firm believes KYV-101’s pivotal programs in Myasthenia Gravis and Stiff-Person Syndrome are highly de-risked and remain unappreciated by investors. Wells cites a higher probability of success for MG, and believes shares should work up into the pivotal SPS read out in the first half of 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics’ KYV-101 Shows Promising Phase II Results in gMG, Supporting Buy Rating
- Kyverna Therapeutics price target raised to $31 from $27 at Wells Fargo
- Kyverna Therapeutics Reports Positive Phase 2/3 Trial Data
- Kyverna Therapeutics Reports Positive Phase 2 Trial Results
- Kyverna Therapeutics announces data from Phase 2 from KYSA-6 clinical trial